Researchers said the reason for this is because of “remarkable advances” in medical research and cancer prevention, detection, diagnosis and treatment. Between August 1, 2021 and July 31, 2022, for example, the Food and Drug Administration approved eight new anticancer therapeutics, 10 already approved therapeutics for use for new cancer types and two new diagnostic imaging agents.
“We have now a revolution in immune therapies. And when you put that together with the combination of targeted therapies, chemo and radiation therapy, we now have patients that would have died within two years of a diagnosis living 15, 20, 25, 30 years, essentially cured of their malignancies,” AACR President Lisa Coussens said.
However, this progress is not equal, and many populations “continue to shoulder a disproportionate burden of cancer,” the report says.
Comments are closed.